Abstract: Due to lifestyle changes, the prevalence of non-alcoholic fatty liver disease (NAFLD) has increased and thus become one of the most common chronic liver diseases globally. However, adverse outcomes of NAFLD are undervalued and the first licensed drug for NAFLD has not yet been approved. Here, we summarize recent progress in the studies of the mechanism and new therapies of NAFLD, which may provide a better understanding of this disease.